Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Healthcare Biotechnology
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK... see more

TSX:FRX - Post Discussion

Fennec Pharmaceuticals Ord Shs > IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?
View:
Post by AviseAnalytics on Dec 09, 2021 7:08am

IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

$FENC 

Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), citing deficiencies in manufacturing.
 
This marks the second CRL for the Company. which earlier served a CRL for deficiencies in manufacturing in August 2020. Can Fennec Pharmaceuticals successfully address the concerns and obtain an approval for Pedmark?
 
Read on to find out more!

https://www.aviseanalytics.com/is-third-time-the-charm-for-fennec-pharmaceuticals/
Comment by willyk3 on Dec 09, 2021 9:46am
Absolute dud    The fact that they failed at the manufacturing revisions shows that they and their mfg partner  are incompetant at this aspect of the process.  Wonder who that is ?  Drug works...allbeit a dangerous potion...fraught with potential lawsuits if improperly  doled out Maybe they should give Jan a call at Acasti...she sure knows how to execute...LOL
Comment by willyk3 on Dec 13, 2021 8:05am
The obvious solution at this stage is to just sell the darn company (at a discount) to a real pharmaceautical company who  has the capability to complete the process
Fennec Pharmaceuticals Ord Shs
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities